STSA
NASDAQSatsuma Pharmaceuticals Inc.
Satsuma Pharmaceuticals Inc. (STSA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for STSA in the last 30 days. The most recent was published Jun 20, 2023.
Latest news
25 items- SECSEC Form 15-12G filed by Satsuma Pharmaceuticals Inc.15-12G - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- PRSatsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific MeetingDURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-p
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Satsuma Pharmaceuticals Inc. (Amendment)SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
- NEWSSatsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively BuyingThe Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Satsuma Pharmaceuticals The Trade: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) 10% owner Shin Nippon Biomedical Laboratories Ltd acquired a total 30,477,313 shares an average price of $0.91. To acquire these shares, it cost around $27.73 million. The
- SECSEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- SECSEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- SECSEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- INSIDERSEC Form 4 filed by O'Neil Thomas P.4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Shah Rajeev M.4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Takanashi Ken4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Riebe Michael T4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Sandoval Elisabeth4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Soloway Thomas P4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Kollins John A4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Lukatch Heath4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by King Thomas Braxton4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Shin Nippon Biomedical Laboratories, Ltd.4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- INSIDERSEC Form 4 filed by Harsch Mutya4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
- SECSEC Form 25-NSE filed by Satsuma Pharmaceuticals Inc.25-NSE - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
- SECSEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- SECSEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- SECSEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- SECSEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
- SECSEC Form POS AM filed by Satsuma Pharmaceuticals Inc.POS AM - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
STSA FAQ
8 questionsWhat does Satsuma Pharmaceuticals Inc. do?
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.What is the latest news on STSA?
Quantisnow has not tracked any new filings, ratings or press releases for STSA in the last 30 days. The most recent wire item was published on June 20, 2023.Where does STSA stock trade?
Satsuma Pharmaceuticals Inc. (STSA) is listed on NASDAQ.What sector and industry is STSA in?
Satsuma Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Satsuma Pharmaceuticals Inc. go public?
Satsuma Pharmaceuticals Inc. (STSA) completed its IPO in 2019.What are analysts saying about STSA?
Across the last 2 analyst actions on Satsuma Pharmaceuticals Inc., there was 1 upgrade and 0 downgrades. The most recent action was from SVB Leerink: Outperform with a $15.00 price target on 2022-10-10. Recent price targets range from $15.00 to $16.00.What companies are similar to STSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare STSA side-by-side with any of them on Quantisnow.How can I track STSA on Quantisnow?
Quantisnow aggregates Satsuma Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STSA to receive live email and push alerts on every new disclosure.